Nexell launches cellular staining kit:
This article was originally published in Clinica
Nexell Therapeutics has launched its Cytonex ImmunoCytoChemistry Staining Kit for in vitro diagnostic use. The assay is used to help pathologists detect the presence of cells containing cytokeratin in blood and bone marrow specimens from patients with epithelial cell-derived malignancies, such as breast, prostate or colon cancer. Irvine, California-based Nexell's kit, which includes pre-mixed colour-coded reagents, produces on-site results in under three hours. The pre-diluted reagents include a primary antibody cocktail that binds to specific antigenic sites on the target cells, single-step fixation and cell dyes. These differentially stain cytokeratin-positive cells for visual recognition under a light microscope.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.